RISAVIE 550 is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥18 years of age (see Pharmacology: Pharmacodynamics under Actions).
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Other Services
Country
Account